Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Fréderique Guette"'
Autor:
Pierre Dieu, Mourad Kaghad, Annette Roasio, Nathalie Hasel, Amélie Aries, Stéphane Yvon, Jan H. Lupker, Fréderique Guette, Constantino Diaz, Pascual Ferrara, Brigitte Miloux, Claude Feuillerat, Edgardo A. Ferrán, Danielle Albène, Christine Labit-Le Bouteiller, Aimée Cambon-Kernëis, Eric Perret, Marie-Françoise Jamme
Publikováno v:
Molecular Informatics. 32:213-229
The DLS-VS strategy was developed as an integrated method for identifying chemical modulators for orphan GPCRs. It combines differential low-throughput screening (DLS) and virtual screening (VS). The two cascaded techniques offer complementary advant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e85cf33c32baaf7a33295d515bf16a6
https://doi.org/10.1002/minf.201200047
https://doi.org/10.1002/minf.201200047
Autor:
Su Wang, Denis Loyaux, Michael A. Smith, Catherine Déon, Jean-Claude Guillemot, Steven A. Goldman, Sébastien Roudières, Philippe Fabre, Paul R. August, Fréderique Guette, Pascual Ferrara, François Autelitano, Qinggong Ping, Romane Auvergne, Vasudeo Badarinarayana, Sridaran Natesan
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e110316 (2014)
PLoS ONE
PLoS ONE
Glioblastoma multiform (GBM) remains clinical indication with significant "unmet medical need". Innovative new therapy to eliminate residual tumor cells and prevent tumor recurrences is critically needed for this deadly disease. A major challenge of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be888de4535a76673956d7b3e3ee8f3c
http://europepmc.org/articles/PMC4216004?pdf=render
http://europepmc.org/articles/PMC4216004?pdf=render
Autor:
François Autelitano, Denis Loyaux, Sébastien Roudières, Catherine Déon, Frédérique Guette, Philippe Fabre, Qinggong Ping, Su Wang, Romane Auvergne, Vasudeo Badarinarayana, Michael Smith, Jean-Claude Guillemot, Steven A Goldman, Sridaran Natesan, Pascual Ferrara, Paul August
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e110316 (2014)
Glioblastoma multiform (GBM) remains clinical indication with significant "unmet medical need". Innovative new therapy to eliminate residual tumor cells and prevent tumor recurrences is critically needed for this deadly disease. A major challenge of
Externí odkaz:
https://doaj.org/article/519cf8f63c9a4d6394e745c03be6e03d